SEC Comment Letter for Adaptive Biotechnologies Corp (ADPT) (CIK 0001478320) (ADPT) — Jan 15, 2020

Adaptive Biotechnologies Corp (ADPT) (CIK 0001478320)
Date: Jan. 15, 2020 · CIK: 0001478320 · Accession: 0000000000-20-000375

View on Edgar

AI Filing Summary & Sentiment

Date

January 15, 2020

Author

Not clearly detected

Form

UPLOAD

Company

Adaptive Biotechnologies Corp (ADPT) (CIK 0001478320)

Letter

January 15, 2020 Chad Robins Chief Executive Officer Adaptive Biotechnologies Corporation 1551 Eastlake Avenue East, Suite 200 Seattle, Washington 98102 Re:Adaptive Biotechnologies Corporation Draft Registration Statement on Form S-1 Submitted January 9, 2020 CIK No. 0001478320 Dear Mr. Robins: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew Ledbetter, Esq.

Show Raw Text

January 15, 2020
Chad Robins
Chief Executive Officer
Adaptive Biotechnologies Corporation
1551 Eastlake Avenue East, Suite 200
Seattle, Washington 98102
Re:Adaptive Biotechnologies Corporation
Draft Registration Statement on Form S-1
Submitted January 9, 2020
CIK No. 0001478320
Dear Mr. Robins:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Andrew Ledbetter, Esq.

SecProbe.io